Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-02-2024 | Bone Metastasis | Research

In vivo validation of the functional role of MicroRNA-4638-3p in breast cancer bone metastasis

Authors: R. L. Akshaya, I. Saranya, G. Margaret Salomi, P. Shanthi, R. Ilangovan, P. Venkataraman, N. Selvamurugan

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2024

Abstract

Purpose

Skeletal metastases are increasingly reported in metastatic triple-negative breast cancer (BC) patients. We previously reported that TGF-β1 sustains activating transcription factor 3(ATF3) expression and is required for cell proliferation, invasion, and bone metastasis genes. Increasing studies suggest the critical regulatory function of microRNAs (miRNAs) in governing BC pathogenesis. TGF-β1 downregulated the expression of miR-4638-3p, which targets ATF3 in human BC cells (MDA-MB-231). In the present study, we aimed to identify the functional role of miR-4638-3p in BC bone metastasis by the caudal artery injection of the MDA-MB-231 cells overexpressing mir-4638 in the mice.

Methods

MDA-MB-231 cells overexpressing miR-4638 were prepared by stable transfections. Reverse transcriptase quantitative PCR was carried out to determine the expression of endogenous miR-4638-3p and bone resorption marker genes. X-ray, micro-CT, and Hematoxylin & Eosin studies were used to determine osteolytic lesions, trabecular structure, bone mineral density, and micrometastasis of cells.

Results

The mice injected with MDA-MB-231 cells overexpressing miR-4638-3p decreased the expression of bone resorption marker genes, compared to MDA-MB-231 cells injection. Reduced osteolytic lesions and restored bone density by MDA-MB-231 cells overexpressing miR-4638-3p were observed. Similarly, the mice injected with MDA-MB-231 cells overexpressing miR-4638-3p showed a better microarchitecture of the trabecular network. A few abnormal cells seen in the femur of MDA-MB-231 cells-injected mice were not found in MDA-MB-231 cells overexpressing miR-4638.

Conclusion

The identified functional role of ATF3 targeting miR-4638-3p in BC bone metastasis in vivo suggests its candidature as BC therapeutics in the future.

Akshaya RL, Rohini M, He Z, Partridge NC, Selvamurugan N (2022) MiR-4638–3p regulates transforming growth factor-β1-induced activating transcription factor-3 and cell proliferation, invasion, and apoptosis in human breast cancer cells. Int J Biol Macromol 222(PtB):1974–1982. https://doi.org/10.1016/j.ijbiomac.2022.09.286CrossRefPubMed

Akshaya AL, Saranya I, Selvamurugan N (2023) MircroRNAs mediated interaction of tumor microenvironment cells with breast cancer cells during bone metastasis. Breast Cancer 6:910–925. https://doi.org/10.1007/s12282-023-01491-0CrossRef

Asif A, Mohsin H, Tanvir R, Rehman Y (2017) Revisiting the mechanisms involved in calcium chloride induced bacterial transformation. Front Microbiol 8:2169. https://doi.org/10.3389/fmicb.2017.02169CrossRefPubMedCentralPubMed

Bahena-Ocampo I, Espinosa M, Ceballos-Cancino G, Lizarraga F, Campos-Arroyo D, Schwarz A, Maldonado V, Melendez-Zajgla J, Garcia-Lopez P (2016) miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation. EMBO Rep 17(5):648–658. https://doi.org/10.15252/embr.201540678CrossRefPubMedCentralPubMed

Bertoli G, Cava C, Castiglioni I (2015) MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 5(10):1122–1143. https://doi.org/10.7150/thno.11543CrossRefPubMedCentralPubMed

Bevacqua E, Ammirato S, Cione E, Curcio R, Dolce V, Tucci P (2022) The potential of MicroRNAs as non-invasive prostate cancer biomarkers: a systematic literature review based on a machine learning approach. Cancers 14(21):5418. https://doi.org/10.3390/cancers14215418CrossRefPubMedCentralPubMed

Bhat SA, Majid S, Hassan T (2019) MicroRNAs and its emerging role as breast cancer diagnostic marker- A review. Adv Biomark Sci Technol 1:1–8CrossRef

Campbell JP, Merkel AR, Masood-Campbell SK, Elefteriou F, Sterling JA (2021) Models of bone metastasis. J vis Exp 67:e4260

Campos-Parra AD, Mitznahuatl GC, Pedroza-Torres A, Romo RV, Reyes FIP, López-Urrutia E, Pérez-Plasencia C (2017) Micro-RNAs as potential predictors of response to breast cancer systemic therapy: future clinical implications. Int J Mol Sci 18(6):1182. https://doi.org/10.3390/ijms18061182CrossRefPubMedCentralPubMed

Chasampalioti M, Green AR, Ellis IO, Rakha EA, Jackson AM, Spendlove I, Ramage JM (2019) Connexin 43 is an independent predictor of patient outcome in breast cancer patients. Breast Cancer Res Treat 174(1):93–102. https://doi.org/10.1007/s10549-018-5063-9CrossRefPubMed

Chen C, Pan Y, Bai L, Chen H, Duan Z, Si Q, Zhu R, Chuang TH, Luo Y (2021) MicroRNA-3613-3p functions as a tumor suppressor and represents a novel therapeutic target in breast cancer. Breast Cancer Res: BCR 23(1):12. https://doi.org/10.1186/s13058-021-01389-9CrossRefPubMedCentralPubMed

Chiou AE, Liu C, Moreno-Jiménez I, Tang T, Wagermaier W, Dean MN, Fischbach C, Fratzl P (2021) Breast cancer-secreted factors perturb murine bone growth in regions prone to metastasis. Sci Adv 7(12):2283. https://doi.org/10.1126/sciadv.abf2283CrossRef

Deen NNA, Lanman NA, Chittiboyina S, Fostok S, Nasr R, Lelièvre S, Talhouk R (2022) Over-expression of miR-183-5p or miR-492 triggers invasion and proliferation and loss of polarity in non-neoplastic breast epithelium. Sci Rep 12(1):21974. https://doi.org/10.1038/s41598-022-25663-8CrossRef

Dillekås H, Rogers MS, Straume O (2019) Are 90% of deaths from cancer caused by metastases? Cancer Med 8(12):5574–5576. https://doi.org/10.1002/cam4.2474CrossRefPubMedCentralPubMed

Ding L, Li J, Wu C, Yan F, Li X, Zhang S (2020) A self-assembled RNA-triple helix hydrogel drug delivery system targeting triple-negative breast cancer. Journal of Materials Chemistry B 8(16):3527–3533. https://doi.org/10.1039/c9tb01610dCrossRefPubMed

Farhoodi HP, Segaliny AI, Wagoner ZW, Cheng JL, Liu L, Zhao W (2020) Optimization of a syngeneic murine model of bone metastasis. Journal of Bone Oncology 23:100298. https://doi.org/10.1016/j.jbo.2020.100298CrossRefPubMedCentralPubMed

Geffre CP, Pond E, Pond GD, Sroka IC, Gard JM, Skovan BA, Meek WE, Landowski TH, Nagle RB, Cress AE (2015) Combined micro-CT and histopathology for evaluation of skeletal metastasis in live animals. American Journal of Translational Research 7(2):348–355PubMedCentralPubMed

Gokulnath M, Swetha R, Thejaswini G, Shilpa P, Selvamurugan N (2017) Transforming growth factor-β1 regulation of ATF-3, c-Jun and JunB proteins for activation of matrix metalloproteinase-13 gene in human breast cancer cells. Int J Biol Macromol 94(PtA):370–377. https://doi.org/10.1016/j.ijbiomac.2016.10.026CrossRefPubMed

Guo X, Gao C, Yang DH, Li S (2023) Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance. Drug Resist Updat 67:100937. https://doi.org/10.1016/j.drup.2023.100937CrossRefPubMed

Haider MT, Smit DJ, Taipaleenmäki H (2022) MicroRNAs: emerging regulators of metastatic bone disease in breast cancer. Cancers 14(3):729. https://doi.org/10.3390/cancers14030729CrossRefPubMedCentralPubMed

Han Y, Nakayama J, Hayashi Y, Jeong S, Futakuchi M, Ito E, Watanabe S, Semba K (2020) Establishment and characterization of highly osteolytic luminal breast cancer cell lines by intracaudal arterial injection. Genes Cells 25(2):111–123. https://doi.org/10.1111/gtc.12743CrossRefPubMed

Hering S, Isken E, Knabbe C, Janott J, Jost C, Pommer A, Muhr G, Schatz H, Pfeiffer AF (2001) TGFbeta1 and TGFbeta2 mRNA and protein expression in human bone samples. Exp Clin Endocrinol Diabetes 109(4):217–226. https://doi.org/10.1055/s-2001-15109CrossRefPubMed

Huang C, Chen R, Zheng F, Tang Y, Wang X, Chen Z, Lai X (2021) Inhibitory role of ATF3 in gastric cancer progression through regulating cell EMT and stemness. Cancer Cell Int 21(1):127. https://doi.org/10.1186/s12935-021-01828-9CrossRefPubMedCentralPubMed

Kim Y, Brodt MD, Tang SY, Silva MJ (2021) Micro-CT for scanning and analysis of mouse bones. In: Hilton MJ (ed) Methods in molecular biology (Clifton, N.J). Springer, NY, pp 169–198. https://doi.org/10.1007/978-1-0716-1028-2_11CrossRef

Ku HC, Cheng CF (2020) Master regulator activating transcription factor 3 (ATF3) in metabolic homeostasis and cancer. Front Endocrinol 11:556. https://doi.org/10.3389/fendo.2020.00556CrossRef

Kuchimaru T, Kizaka-Kondoh S (2021) A murine bone metastasis model using caudal artery injection and bioluminescence imaging. In: Kim S-B (ed) Methods in molecular biology. N.J, Clifton, pp 37–42. https://doi.org/10.1007/978-1-0716-1258-3_4CrossRef

Kuthethur R, Adiga D, Kandettu A, Jerome MS, Mallya S, Mumbrekar KD, Kabekkodu SP, Chakrabarty S (2023) MiR-4521 perturbs FOXM1-mediated DNA damage response in breast cancer. Front Mol Biosci 10:1131433. https://doi.org/10.3389/fmolb.2023.1131433CrossRefPubMedCentralPubMed

Kwok S, Rittling SR, Partridge NC, Benson CS, Thiyagaraj M, Srinivasan N, Selvamurugan N (2009) Transforming growth factor-beta1 regulation of ATF-3 and identification of ATF-3 target genes in breast cancer cells. J Cell Biochem 108(2):408–414. https://doi.org/10.1002/jcb.22267CrossRefPubMed

Li S (2021) The basic characteristics of extracellular vesicles and their potential application in bone sarcomas. J Nanobiotechnol 19(1):277. https://doi.org/10.1186/s12951-021-01028-7CrossRef

Li Y, Li N, Yu X, Huang K, Zheng T, Cheng X, Zeng S, Liu X (2018) Hematoxylin and eosin staining of intact tissues via delipidation and ultrasound. Sci Rep 8(1):12259. https://doi.org/10.1038/s41598-018-30755-5CrossRefPubMedCentralPubMed

Li X, Deng S, Pang X, Song Y, Luo S, Jin L, Pan Y (2019) LncRNA NEAT1 silenced miR-133b promotes migration and invasion of breast cancer cells. Int J Mol Sci 20(15):3616. https://doi.org/10.3390/ijms20153616CrossRefPubMedCentralPubMed

Li S, Liu F, Zheng K, Wang W, Qiu E, Pei Y, Wang S, Zhang J, Zhang X (2021) CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis. Mol Cancer 20(1):161. https://doi.org/10.1186/s12943-021-01453-0CrossRefPubMedCentralPubMed

Li S, Kang Y, Zeng Y (2023) Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis. Biochim Et Biophys Acta (BBA) Revi Cancer 1879:189033. https://doi.org/10.1016/j.bbcan.2023.189033CrossRef

Liu J, Li D, Dang L, Liang C, Guo B, Lu C, He X, Cheung HY, He B, Liu B, Li F, Lu J, Wang L, Shaikh AB, Jiang F, Lu C, Peng S, Zhang Z, Zhang BT, Pan X, Zhang G (2017) Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer. Sci Rep 7:40487. https://doi.org/10.1038/srep40487CrossRefPubMedCentralPubMed

Liu D, Wu J, Lin C, Andriani L, Ding S, Shen K, Zhu L (2020) Breast subtypes and prognosis of breast cancer patients with initial bone metastasis: a population-based study. Front Oncol 10:580112. https://doi.org/10.3389/fonc.2020.580112CrossRefPubMedCentralPubMed

Malavika D, Shreya S, Raj Priya V, Rohini M, He Z, Partridge NC, Selvamurugan N (2020) miR-873-3p targets HDAC4 to stimulate matrix metalloproteinase-13 expression upon parathyroid hormone exposure in rat osteoblasts. J Cell Physiol 235(11):7996–8009. https://doi.org/10.1002/jcp.29454CrossRefPubMed

Marconi R, Serafini A, Giovanetti A, Bartoleschi C, Pardini MC, Bossi G, Strigari L (2019) Cytokine modulation in breast cancer patients undergoing radiotherapy: a revision of the most recent studies. Int J Mol Sci 20(2):382. https://doi.org/10.3390/ijms20020382CrossRefPubMedCentralPubMed

O’Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 9:402. https://doi.org/10.3389/fendo.2018.00402CrossRef

Park MK, Lee CH, Lee H (2018) Mouse models of breast cancer in preclinical research. Lab Anim Res 34(4):160–165. https://doi.org/10.5625/lar.2018.34.4.160CrossRefPubMedCentralPubMed

Rohini M, Gokulnath M, Miranda PJ, Selvamurugan N (2018) miR-590-3p inhibits proliferation and promotes apoptosis by targeting activating transcription factor 3 in human breast cancer cells. Biochimie 154:10–18. https://doi.org/10.1016/j.biochi.2018.07.023CrossRefPubMed

Rohini M, Arumugam B, Vairamani M, Selvamurugan N (2019) Stimulation of ATF3 interaction with Smad4 via TGF-β1 for matrix metalloproteinase 13 gene activation in human breast cancer cells. Int J Biol Macromol 134:954–961. https://doi.org/10.1016/j.ijbiomac.2019.05.062CrossRefPubMed

Rohini M, Vairamani M, Selvamurugan N (2021) TGF-β1-stimulation of NFATC2 and ATF3 proteins and their interaction for matrix metalloproteinase 13 expression in human breast cancer cells. Int J Biol Macromol 192:1325–1330. https://doi.org/10.1016/j.ijbiomac.2021.10.099CrossRefPubMed

Sajjad H, Imtiaz S, Noor T, Siddiqui YH, Sajjad A, Zia M (2021) Cancer models in preclinical research: a chronicle review of advancement in effective cancer research. Anim Models Exp Med 4(2):87–103. https://doi.org/10.1002/ame2.12165CrossRef

Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, Wulf-Goldenberg A, Stanzer S, Rinnerthaler G, Stoeger H, Bauernhofer T, Haybaeck J, Hoefler G, Jahn SW, Parrella P, Calin GA, Pichler M (2019) MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. Breast Cancer Res: BCR 21(1):20. https://doi.org/10.1186/s13058-019-1104-5CrossRefPubMedCentralPubMed

Shim J, Iwaya C, Ambrose CG, Suzuki A, Iwata J (2022) Micro-computed tomography assessment of bone structure in aging mice. Sci Rep 12(1):8117. https://doi.org/10.1038/s41598-022-11965-4CrossRefPubMedCentralPubMed

Shinde SS, Ahmed S, Malik JA, Hani U, Khanam A, Ashraf Bhat F, Ahmad Mir S, Ghazwani M, Wahab S, Haider N, Almehizia AA (2023) Therapeutic delivery of tumor suppressor miRNAs for breast cancer treatment. Biology 12(3):467. https://doi.org/10.3390/biology12030467CrossRefPubMedCentralPubMed

Shovon MSH, Islam MJ, Nabil MNAK, Molla MM, Jony AI, Mridha MF (2022) Strategies for enhancing the multi-stage classification performances of HER2 breast cancer from hematoxylin and eosin images. Diagnostics (basel, Switzerland) 12(11):2825. https://doi.org/10.3390/diagnostics12112825CrossRefPubMed

Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708CrossRefPubMed

Sun C, Wang B, Li J, Shangguan J, Figini M, Zhou K, Pan L, Ma Q, Zhang Z (2018) Quantitative measurement of breast carcinoma fibrosis for the prediction in the risk of bone metastasis. Am J Transl Res 10(6):1852–1859PubMedCentralPubMed

Tandon N, Thakkar KN, LaGory EL, Liu Y, Giaccia AJ (2018) Generation of stable expression mammalian cell lines using lentivirus. Bio-Protoc 8(21):e3073. https://doi.org/10.21769/BioProtoc.3073CrossRefPubMedCentralPubMed

Ubellacker JM, McAllister SS (2016) The unresolved role of systemic factors in bone metastasis. J Bone Oncol 5(3):96–99. https://doi.org/10.1016/j.jbo.2016.03.009CrossRefPubMedCentralPubMed

Wang H, Tan Z, Hu H, Liu H, Wu T, Zheng C, Wang X, Luo Z, Wang J, Liu S, Lu Z, Tu J (2019) microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC Cancer 19(1):738. https://doi.org/10.1186/s12885-019-5951-3CrossRefPubMedCentralPubMed

Yan L, Gaddis S, Coletta LD, Repass J, Powell KL, Simper MS, Chen Y, Byrom M, Zhong Y, Lin K, Liu B, Lu Y, Shen J, MacLeod MC (2021) ATF3-induced mammary tumors exhibit molecular features of human basal-like breast cancer. Int J Mol Sci 22(5):2353. https://doi.org/10.3390/ijms22052353CrossRefPubMedCentralPubMed

Yin X, Dewille JW, Hai T (2008) A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene 27(15):2118–2127. https://doi.org/10.1038/sj.onc.1210861CrossRefPubMed

Yin X, Wolford CC, Chang YS, McConoughey SJ, Ramsey SA, Aderem A, Hai T (2010) ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells. J Cell Sci 123(Pt 20):3558–3565. https://doi.org/10.1242/jcs.064915CrossRefPubMedCentralPubMed

Young SAE, Heller AD, Garske DS, Rummler M, Qian V, Ellinghaus A, Duda GN, Willie BM, Gruneboom A, Cipitria A (2023) From breast cancer cell homing to the onset of early bone metastasis: dynamic bone (re)modeling as a driver of osteolytic disease. BioRxiv 5:66

Yu Y, Li K, Peng Y, Wu W, Chen F, Shao Z, Zhang Z (2023) Animal models of cancer metastasis to the bone. Front Oncol 13:1165380. https://doi.org/10.3389/fonc.2023.1165380CrossRefPubMedCentralPubMed

Zhong L, Miller HD, Zhang Y, Jin B, Ge D, You Z (2020) Intra-arterial injection to create bone metastasis of prostate cancer in mice. Am J Clin Exp Urol 8(4):93–100PubMedCentralPubMed

Zhou J, Sun X, Zhang X, Yang H, Jiang Z, Luo Q, Liu Y, Wang G (2022) miR-107 is involved in the regulation of NEDD9-mediated invasion and metastasis in breast cancer. BMC Cancer 22(1):533. https://doi.org/10.1186/s12885-022-09603-3CrossRefPubMedCentralPubMed

Title: In vivo validation of the functional role of MicroRNA-4638-3p in breast cancer bone metastasis
Authors: R. L. Akshaya
I. Saranya
G. Margaret Salomi
P. Shanthi
R. Ilangovan
P. Venkataraman
N. Selvamurugan
Publication date: 01-02-2024
Publisher: Springer Berlin Heidelberg
Keywords: Bone Metastasis
Breast Cancer
Breast Cancer
Published in: Journal of Cancer Research and Clinical Oncology / Issue 2/2024
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05601-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2024

Exploring the expression and clinical significance of the miR-140-3p-HOXA9 axis in colorectal cancer

Effectiveness and safety of intraoperative intraperitoneal 5-Fu drug implantation in patients with colorectal cancer: a retrospective cohort study

A subregion-based RadioFusionOmics model discriminates between grade 4 astrocytoma and glioblastoma on multisequence MRI

Development of a novel lncRNA-derived immune gene score using machine learning-based ensembles for predicting the survival of HCC

Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy

Skeletal muscle extramedullary plasmacytoma transformed into plasmablastic plasmacytoma: a case report

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage